MedPath

Hyaluronic Acid Gels for Lower Lid Retraction

Phase 4
Withdrawn
Conditions
Ectropion
Interventions
Procedure: Hyaluronic acid
Procedure: Saline
Registration Number
NCT01838252
Lead Sponsor
University of California, Los Angeles
Brief Summary

Lid retraction is a difficult problem encountered in oculofacial plastic surgery. It can result from previous surgery, radiotherapy or cicatrizing disease or it may be idiopathic. Whatever the aetiology, the cosmetic appearance is troublesome to patients and, can be damaging to the cornea. The definitive therapy for lid retraction is surgical, and often involves complicated procedures including tissue grafting.

Hyaluronic acid gels (HAG) have been FDA approved for the treatment of facial rhytids by subcutaneous injection and volume addition. These gels have gained wide popularity in for cosmetic applications in filling volume deficit areas. Functional applications in the periorbital area have also been described including the filling of volume deficit anophthalmic orbits, ectropion and loagophthalmos. Additionally, pilot studies have found HAG to be useful in correcting both upper and lower eyelid retraction, with good effect.

The purpose of this investigation is to define the clinical utility of HAG correction of lower eyelid retraction in terms of anatomic (lid position), quantitative (dry eye signs on cornea) and qualitative effects (symptom severity).

Our hypothesis is that HAG correction of lower eyelid retraction will improve patient comfort, clinical signs of dry eye and aesthetic self image.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. Lower eyelid retraction of >1mm in one or both eyes.
  2. Complaints of either significant ocular symptoms (OSDI>13) or cosmetic deformity associated with the eyelid retraction.
Read More
Exclusion Criteria
  1. Age less than 21 years: due to lack of data on safety for HAG fillers in pediatric population
  2. Age over 65 years of age: as HAG filler effect may be different in this population
  3. Are pregnant or nursing: as there is little safety data on potential teratogenicity of HAG fillers
  4. Have a demonstrated allergy to HAG fillers or lidocaine
  5. Have a current infection, skin sore, pimple, rash, hive or cyst over the injection site: to avoid worsening the infection or transmitting it
  6. Have a bleeding disorder or currently taking blood-thinning medications such as Coumadin or heparin on a daily basis.
  7. Currently active stage Thyroid Eye Disease
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Hyaluronic acidHyaluronic acidPatients in this arm will receive hyaluronic acid fillers to the lower lid.
SalineSaline-
Primary Outcome Measures
NameTimeMethod
Lower eyelid position6 weeks

Decrease in inferior scleral show

Secondary Outcome Measures
NameTimeMethod
Subjective dry eye symptoms6 weeks

Ocular surface disease index score

Objective dry eye signs6 weeks

Oxford staining score

Trial Locations

Locations (1)

Jules Stein Eye Institute

🇺🇸

Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath